진행성 위암 환자에서 Heptaplatin과 5-Fluorouracil 복합요법의 임상효과
Clinical Effects of the Combination Chemotherapy of Heptaplatin and 5-Fluorouracil in Advanced Gastric Cancer
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Heptaplatin is a new platinum derivative with antitumor activity against gastric cancer. Preclinical studies showed that it is less toxic than other platinum analogues. The purpose of this study is to evaluate the efficacy and toxicity of the combination therapy of heptaplatin and 5-fluorouracil in Korean advanced gastric cancer patients. This study was investigated retrospectively. The patients group consisted of 65 advanced gastric cancer patients with no prior radiotherapy. All patients received heptaplatin 400 mg/m2 by 2-3 hour infusion on Day 1 and 5-FU 1000 mg/m2 by 12-24 hour continuous infusion for 5 days. After the first cycle, subsequent doses were adjusted according to the toxicity. Courses were repeated every 28 days. As results, objective response occurred in 16 patients (24.6%). Two were complete and 14 were partial response. Median progression free survival was 32 weeks with 29% of patients progression free at 1 year. The most common hematologic toxicity was anemia. Grade 3 or 4 anemia was seen at 2.7% of treatment cycles. Grade 3 or higher leucopenia was seen at 1.2% of cycles. Grade 3 or 4 neutropenia and thrombocytopenia occurred at 6.1% and 1.5% of cycles, respectively. The most common nonhematologic toxicity was proteinuria. Though no patients experienced grade 3 or 4 proteinuria, proteinuria was a considerable factor for this chemotherapy. Grade 3 or higher gastrointestinal toxicities were nausea and vomiting (4.6% of patients) and diarrhea (1.5% of patients). Grade 2 renal toxicity with elevation of serum creatinine was seen in 0.3% of cycles, which is less than that of other platinum analogues. This study showed that combination therapy of heptaplatin and 5-FU have modest antitumor activity against advanced gastric cancer without severe renal toxicity.
참고문헌 (31)
- Lambert R, "Incidence and Mortality from Stomach Cancer in Japan", pp.811~8 (2002)
- 김진복, "위암의 치료성적", 26, pp.637~42 (1978)
- Muto M, "Improvement in the end results of surgical treatment of gastric cancer", 25, pp.3~8 (1968)
- Wills J, "Current status of chemotherapy for gastric cancer", 25, pp.3~8 (1989)
- The therapy stomach cancer, "Principles of cancer treatment", pp.420~8 (1982), McGraw-Hill
- Macdonald JS, "Chemotherapy of advanced gastric cancer", pp.4 42~9
- MacDonald JS, "combination chemotherapy for advanced gastric cancer", pp.5 533~6
- Lacave AJ, "Cisplatin as second-line chemotherapy in advanced gastric adenocarcinoma:a phase II study of the EORTC gastrointestinal tract cancer cooperative group", 21, pp.1321~4 (1985)
- Preusser P, "Phase II study with the combination etoposide,doxorubicin and cisplatin in advanced measurable gastric cancer", 7, pp.1310~7 (1989)
- Ohtsu A, "Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer report from the Japan clinical oncology group", pp.2091~3
- Kim DK, "Antitumor activity of cis-malonato [ as an anticancer agent 1996", ami(methyl), pp.5 3 131~7
- Nagai N, "Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients", 39, pp.131~7 (1996)
- Campbell AB, "Relationship to cisplatin dose and nephrotoxicity", 67, pp.169~72 (1993)
- Kelsen DP, "Cisplatin nephrotoxicity correlation with plasma platinum concentrations", 8, pp.77~80 (1985)
- Rece PA, "Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients with cisplatin:relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity", 5, pp.304~9 (1987)
- Jacobs C, "24 - hour infusion of cis-platinum in head and neck cancers", 42, pp.2135~40 (1978)
- Posner MR, "A Phase I trial of continuous infusion cisplatin", pp.15~8
- Salen P, "A new dose schedule with minimal toxicity", pp.837~40
- Kim NK, "Phase II clinical trial of SKI-2053R a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma", 86(7), pp.1109~1115 (1999)
- Geoffroy F, "Chemotherapy of advanced gastrointestinal cancer", 6, pp.427~434 (1994)
- Dougherty JB, "Multimodality therapy of esophageal and gastric cancer American Society of Clinical Oncology", pp.173~83 (1993)
- Platinum (II) in patients with advanced malignancies, , 2001, 1549~1556
- Havlin KA, "chemotherapy of advanced disease", pp.171~9 (1992), JB Lippincott
- for metastatic gastric cancer, "A Phase II study of 5-fluorouracil" (1933)
- Kim NK, "A Phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil,doxorubicin,and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer", 71, pp.3813~8 (1993)
- Safirstein R, "Cisplatin nephrotoxicity:insight into mechanism", 10, pp.325~ (1987)
- Lee YS, "Subacute toxicity of cis-malonato [", ami(methyl), pp.3 235~54
- Cancer Treat Rep 1979, "Nephrotoxicity of cis-dichlorodiammine platinum"
- Madias NE, "Platinum nephrotoxicity", 62, pp.307~ (1978)
- Wolfgang K, "Microalbuminuria during cisplatin therapy:Relation with pharmacokinetics and implication for nephroprotection", 20, pp.3679~3688 (2000)
- Wolfgang K, "Microalbuminuria during cisplatin therapy:Relation with pharmacokinetics and implication for nephroprotection", 20, pp.3679~3688 (2000)